The Zhitong Finance App learned that Guolian Securities released a research report saying that on November 24, the official website of the National Health and Health Commission published the “Notice on Accomplishing the Prevention and Control of COVID-19 Infections and Other Key Infectious Diseases in Winter and Spring”, which mentioned that “China may face a situation where various respiratory diseases such as COVID-19, influenza, and mycoplasma pneumoniae infection are compounded and prevalent this winter and spring.” The bank said that there is a high incidence of respiratory infectious diseases in winter and spring, and the combination of pathogens such as influenza, COVID-19, and mycoplasma pneumoniae, etc., is stronger than in previous years, which has attracted widespread attention. It believes that vaccination demand for respiratory diseases is expected to be boosted. It is recommended to focus on targets with relatively high performance and low phased valuation.

Beneficial targets: Vaccine: Focus on 100 grams of biotechnology (688276.SH), recommended focus on Hualan Biotech (002007.SZ) and Jindick (688670.SH); testing: recommended focus on Innotek () and Wanfu Biotech (300482.SZ); traditional Chinese medicine: Focus on China Resources 39 (000999.SZ), Kangyuan Pharmaceutical (), and Conn Bei (). It is recommended to focus on Sunflower Pharmaceutical (002737.SZ), Jichuan Pharmaceutical () 688253.SH 600557.SH 600572.SH 600566.SH 。

The main views of Guolian Securities are as follows:

Vaccines are the most effective means of preventing infectious diseases, and the high incidence of influenza is expected to accelerate the release of demand for vaccination. In 2020, China's influenza vaccination rate was only 4.1%. Compared with developed countries, there is a lot of room for improvement in the penetration rate. The COVID-19 pandemic has effectively raised public awareness about vaccination, compounded by the recent spread of respiratory infectious diseases. The bank believes that the demand for vaccination against respiratory diseases is expected to be boosted.

The complex situation of infectious diseases compounded by infections has increased the demand of medical institutions for rapid and accurate etiological testing, and related products have been released rapidly. The symptoms of respiratory infectious diseases are similar, but treatment plans for different pathogens vary greatly. Outpatient emergency care in medical institutions is under pressure for a short period of time. Coupled with the increased acceptance of nucleic acid, antigen, and antibody tests by patients after the COVID-19 pandemic, there was a time when the supply of pathogen testing products was in short supply. According to ex-factory prices, the annual market for respiratory pathogen testing is estimated to be close to 2 billion yuan.

The high incidence of respiratory diseases is driving the performance of proprietary drugs in the respiratory system, and is expected to accelerate the digestion of channel inventory products during the COVID-19 period. For mild cases of influenza, the diagnosis and treatment plan recommends proprietary Chinese medicines for dialectical treatment. Sales of proprietary Chinese medicines with effects such as clearing heat, detoxifying, relieving phlegm, and relieving cough have been clearly boosted, helping to ease the pressure on the high performance base of related targets.